Universitat de Barcelona
2020-06-10T08:05:43Z
2020-12-20T06:10:18Z
2019-12-20
2020-06-10T08:05:43Z
Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...)
Article
Accepted version
English
Anàlisi cost-benefici; Salut pública; Diabetis; Insulina; Portugal; Cost effectiveness; Public health; Diabetes; Insulin; Portugal
Cortex - Publicacoes Tecnicas e Cientificas
Versió postprint del document publicat a: http://www.revportdiabetes.com/rpd-dez-2019/
Revista Portuguesa de Diabetes, 2019, vol. 14, num. 4, p. 141-150
cc-by-nc-nd (c) Cortex - Publicacoes Tecnicas e Cientificas, 2019
http://creativecommons.org/licenses/by-nc-nd/3.0/es
Economia [1045]
